Results 11 to 20 of about 8,176 (156)

Critical Review: The Past, Present, and Future of Small Intestinal Bacterial Overgrowth (SIBO). [PDF]

JGH Open
ABSTRACT Small intestinal bacterial overgrowth (SIBO) has evolved from a severe debilitating illness to a clinical spectrum associated with abnormalities of microbial populations in the small intestine. It is best described as a pathophysiological state that may contribute to symptoms or other pathology in a wide range of gastrointestinal conditions ...
Shah A, Holtmann G, Gibson PR.
europepmc   +2 more sources

Rifaximin Therapy of Irritable Bowel Syndrome [PDF]

, 2012
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by abdominal pain and altered bowel habits in the absence of specific organic pathology.
Saman Sabounchi, David B. Huang, Herbert L. DuPont, Hoonmo L. Koo   +3 more
core   +1 more source

Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin [PDF]

, 2015
The gastrointestinal tract is a complex and dynamic network where an intricate and mutualistic symbiosis modulates the relationship between the host and the microbiota in order to establish and ensure gut homeostasis.
Lopetuso, Loris Riccardo, Scaldaferri, Franco, Gasbarrini, Antonio, Petito, Valentina   +3 more
core   +1 more source

High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome [PDF]

, 2011
John JolleyDepartment of Medicine, University of California, San Francisco, CA, USABackground: To evaluate the efficacy of rifaximin for reduction of gastrointestinal symptoms in patients with irritable bowel syndrome (IBS).Methods: Medical records were ...
null Jolley, Jolley J
core   +2 more sources

Rifaximin in Non-Alcoholic Steatohepatitis: An Open-Label Pilot Study [PDF]

, 2017
Aim Gut microbial dysbiosis is implicated in the pathogenesis of non-alcoholic steatohepatitis (NASH). We investigated downstream effects of gut microbiota modulation on markers of hepatic inflammation, steatosis, and hepatic and peripheral insulin ...
Atkinson, Stephen, Marchesi, Julian R, Julie Stove, Wai, Sann N., Yee, Michael S., Stove, Julie, Goldin, Robert D, Jackson, Nicola, Simon D. Taylor-Robinson, Wai, S.N., Quentin M. Anstee, Holmes, E., Cobbold, Jeremy F.L., Umpleby, A. Margot, Fitzpatrick, Julie, Yee, M.S., Thursz, Mark R., Shojaee-Moradie, Fariba, Fariba Shojaee-Moradie, Umpleby, A.M., Taylor-Robinson, S.D., Holmes, Elaine, Shojaee-Moradie, F., A. Margot Umpleby, Anstee, Quentin M, Thomas, E.L., Ann Smith, Bell, Jimmy D, Fitzpatrick, J., Taylor-Robinson, Simon D, Marchesi, Julian R., Bell, Jimmy D., Thursz, M.R., Goldin, R.D., Julian R. Marchesi, Nicola Jackson, Thursz, Mark R, Atkinson, S., Taylor-Robinson, Simon D., Mark R. Thursz, Anstee, Q.M., Wai, Sann N, Goldin, Robert D., Cobbold, Jeremy FL, Jackson, N.C., Marchesi, Julian Roberto, Julie Fitzpatrick, Smith, A., Thomas, E. Louise, Robert D. Goldin, Stove, J., Smith, Ann, Marchesi, J.R., Jeremy F.L. Cobbold, Umpleby, A Margot, Anstee, Quentin M., Elaine Holmes, Bell, J.D., Stephen Atkinson, Sann N. Wai, E. Louise Thomas, Michael S. Yee, Cobbold, J.F.L., Thomas, E Louise, Yee, Michael S, Jimmy D. Bell   +65 more
core   +1 more source

Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy [PDF]

, 2017
Daniela Paola Roggeri, Alessandro Roggeri ProCure Solutions, Nembro, Bergamo, Italy Purpose: Hepatic encephalopathy (HE) is associated with a reduced survival, an increased risk of hospitalization for recurrences, and a reduced health-related ...
Roggeri DP, Roggeri A, Alessandro Roggeri, Daniela Paola Roggeri   +3 more
core   +2 more sources

RIFAXIMIN INDUCED HYPONATREMIA: A CASE REPORT [PDF]

, 2016
Rifaximin is one of the common drugs used in clinical practice in the management of traveler’s diarrhea, irritable bowel syndrome (IBS), and hepaticencephalopathy. Hyponatremia is one of the rare side effects of this drug. We hereby present the case of a
Shalini Upadhyay, Anjalika Gupta, Prabhat Agrawal, Manish Bansal   +3 more
core   +4 more sources

Correlation networks before and after rifaximin. [PDF]

, 2013
Legend common for figures 4A, 4B and 4C: The complex correlation network represented parameters that were linked with a correlation coefficient >0.6 (negative or positive) and with a p value 0.6 or
Phillip B. Hylemon (253333), Andmorgan Fisher (397174), Kalyani Daita (397170), Arun J. Sanyal (306877), Melanie B. White (397173), R. Todd Stravitz (397167), Pamela Monteith (397171), Douglas M. Heuman (397165), Masoumeh Sikaroodi (255013), Huzefa Rangwala (353533), Nicole A. Noble (397172), Patrick M. Gillevet (106128), Jasmohan S. Bajaj (397164), Richard K. Sterling (397166), Jason M. Ridlon (397169), Michael Fuchs (397168)   +15 more
core   +1 more source

Rifaximin Treatment in Hepatic Encephalopathy [PDF]

, 2010
Background Hepatic encephalopathy is a chronically debilitating complication of hepatic cirrhosis. The efficacy of rifaximin, a minimally absorbed antibiotic, is well documented in the treatment of acute hepatic encephalopathy, but its efficacy for ...
Frederick, Todd, Forbes, William P., Mullen, Kevin D., Teperman, Lewis, Beavers, Kimberly, Huang, Shirley, Poordad, Fred, Leevy, Carroll B., Sheikh, Muhammad Y., Merchant, Kunal, Hillebrand, Donald, Neff, Guy, Bass, Nathan M., Sigal, Samuel, Bortey, Enoch, Sanyal, Arun J., Shaw, Audrey   +16 more
core   +2 more sources

Solution Structure of Rifaximin and its Synthetic Derivative Rifaximin OR determined by Experimental NMR and Theoretical Simulation Methods [PDF]

, 2004
The solution structure of rifaximin and its derivative rifaximin OR (open ring) was determined by combining NMR experimental results, theoretical simulation of two-dimensional NMR spectra by complete relaxation matrix analysis (CORMA), and molecular ...
Bonechi, Claudia, Donati, Alessandro, Martini, S., Rossi, Claudio, Corbini, Gianfranco   +4 more
core   +1 more source